MX2022006630A - Uso de reboxetina para tratar los trastornos del sistema nervioso. - Google Patents
Uso de reboxetina para tratar los trastornos del sistema nervioso.Info
- Publication number
- MX2022006630A MX2022006630A MX2022006630A MX2022006630A MX2022006630A MX 2022006630 A MX2022006630 A MX 2022006630A MX 2022006630 A MX2022006630 A MX 2022006630A MX 2022006630 A MX2022006630 A MX 2022006630A MX 2022006630 A MX2022006630 A MX 2022006630A
- Authority
- MX
- Mexico
- Prior art keywords
- reboxetine
- nervous system
- system disorders
- treat nervous
- esreboxetine
- Prior art date
Links
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 title abstract 4
- 229960003770 reboxetine Drugs 0.000 title abstract 4
- 208000012902 Nervous system disease Diseases 0.000 title 1
- CBQGYUDMJHNJBX-OALUTQOASA-N (2S)-2-[(S)-(2-ethoxyphenoxy)-phenylmethyl]morpholine Chemical compound CCOC1=CC=CC=C1O[C@@H](C=1C=CC=CC=1)[C@H]1OCCNC1 CBQGYUDMJHNJBX-OALUTQOASA-N 0.000 abstract 3
- 229950008247 esreboxetine Drugs 0.000 abstract 3
- 201000003631 narcolepsy Diseases 0.000 abstract 3
- 208000023046 narcolepsy-cataplexy syndrome Diseases 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En el presente documento se describen los métodos para el tratamiento de la narcolepsia con cataplexia, los cuales comprenden la administración de la reboxetina (la que incluye la esreboxetina) a un ser humano que lo necesite. La reboxetina (la que incluye la esreboxetina) también se puede utilizar en la elaboración de un medicamento para el tratamiento de la narcolepsia con cataplexia. También se dan a conocer en este documento los kits que comprenden una composición farmacéutica que comprende la reboxetina (la que incluye la esreboxetina) y las instrucciones para usar la composición farmacéutica para el tratamiento de la narcolepsia con cataplexia en un ser humano.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962943077P | 2019-12-03 | 2019-12-03 | |
| US201962946295P | 2019-12-10 | 2019-12-10 | |
| US16/740,329 US20200147093A1 (en) | 2018-10-15 | 2020-01-10 | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| US16/740,410 US20200147095A1 (en) | 2018-10-15 | 2020-01-11 | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| US16/740,411 US20200147096A1 (en) | 2018-10-15 | 2020-01-11 | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| US16/740,409 US11351175B2 (en) | 2018-10-15 | 2020-01-11 | Use of reboxetine to treat narcolepsy |
| PCT/US2020/062560 WO2021113163A1 (en) | 2019-12-03 | 2020-11-30 | Use of reboxetine to treat nervous system disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006630A true MX2022006630A (es) | 2022-06-24 |
Family
ID=81851750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006630A MX2022006630A (es) | 2019-12-03 | 2020-11-30 | Uso de reboxetina para tratar los trastornos del sistema nervioso. |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP4069244A4 (es) |
| JP (1) | JP2023504685A (es) |
| KR (1) | KR20220108122A (es) |
| CN (1) | CN114746097A (es) |
| AU (2) | AU2020395082A1 (es) |
| BR (1) | BR112022010677A2 (es) |
| CA (1) | CA3163505A1 (es) |
| CO (1) | CO2022007507A2 (es) |
| CR (1) | CR20220247A (es) |
| IL (1) | IL293536A (es) |
| MX (1) | MX2022006630A (es) |
| PE (1) | PE20230181A1 (es) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2247572T3 (es) * | 1999-07-01 | 2006-03-01 | PHARMACIA & UPJOHN COMPANY LLC | (s,s)-reboxetina para tratar las cefaleas migrañosas. |
| PL197983B1 (pl) * | 1999-07-01 | 2008-05-30 | Upjohn Co | Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku |
| AU2008248382B2 (en) * | 2007-05-07 | 2013-07-18 | Chelsea Therapeutics, Inc. | Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders |
| WO2014164969A1 (en) * | 2013-03-13 | 2014-10-09 | Aerial Biopharma, Llc | Treatment of cataplexy |
-
2020
- 2020-11-30 JP JP2022533248A patent/JP2023504685A/ja active Pending
- 2020-11-30 EP EP20895126.9A patent/EP4069244A4/en active Pending
- 2020-11-30 KR KR1020227022167A patent/KR20220108122A/ko not_active Ceased
- 2020-11-30 AU AU2020395082A patent/AU2020395082A1/en not_active Abandoned
- 2020-11-30 PE PE2022000980A patent/PE20230181A1/es unknown
- 2020-11-30 MX MX2022006630A patent/MX2022006630A/es unknown
- 2020-11-30 CA CA3163505A patent/CA3163505A1/en active Pending
- 2020-11-30 CN CN202080083484.4A patent/CN114746097A/zh active Pending
- 2020-11-30 BR BR112022010677A patent/BR112022010677A2/pt unknown
- 2020-11-30 CR CR20220247A patent/CR20220247A/es unknown
- 2020-11-30 IL IL293536A patent/IL293536A/en unknown
-
2022
- 2022-05-31 CO CONC2022/0007507A patent/CO2022007507A2/es unknown
-
2024
- 2024-05-31 AU AU2024203676A patent/AU2024203676A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020395082A1 (en) | 2022-06-09 |
| EP4069244A4 (en) | 2023-12-20 |
| PE20230181A1 (es) | 2023-02-01 |
| BR112022010677A2 (pt) | 2022-08-16 |
| KR20220108122A (ko) | 2022-08-02 |
| CR20220247A (es) | 2022-08-18 |
| CN114746097A (zh) | 2022-07-12 |
| CA3163505A1 (en) | 2021-06-10 |
| IL293536A (en) | 2022-08-01 |
| JP2023504685A (ja) | 2023-02-06 |
| CO2022007507A2 (es) | 2022-06-21 |
| EP4069244A1 (en) | 2022-10-12 |
| AU2024203676A1 (en) | 2024-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025003477A (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| MX2023003677A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| MX2023003678A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| MX2021010058A (es) | Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel. | |
| MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
| ZA202304965B (en) | Combination therapy for treating cancer | |
| MX2025001920A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina | |
| MX2021010683A (es) | Esketamina para el tratamiento de la depresión. | |
| MX2023014484A (es) | Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion. | |
| MX2020001254A (es) | Combinacion terapeutica de un inhibidor tirosina quinasa del egfr de tercera generacion y un inhibidor raf. | |
| MX2023003993A (es) | Tratamiento de trastornos bipolares y psicosis con clorhidrato de dexmedetomidina. | |
| MX2023003675A (es) | Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| MX2024003918A (es) | Agente terapeutico que induce citotoxicidad para usarse en terapia del cancer. | |
| MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
| MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
| ZA202002107B (en) | Use of specific sirna against protein s for the treatment of hemophilia | |
| MY186840A (en) | Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy | |
| EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
| MX2022006630A (es) | Uso de reboxetina para tratar los trastornos del sistema nervioso. | |
| MX2025000682A (es) | Composicion farmaceutica de anticuerpo anti-cd20 y uso de la misma | |
| MX2022000082A (es) | Composiciones terapeuticas y metodos para tratar canceres. | |
| MX2021001228A (es) | Composicion para uso en la prevencion y/o tratamiento de la mucosa genitourinaria. |